Russian Federation: Greater Convergence: IP And Competition Law

Last Updated: 3 October 2016
Article by Ilya Goryachev

Most Read Contributor in Russian Federation, September 2018

Russia is a large market for pharmaceuticals, and has a population of more than 140 million, developed retail chains and a large state procurement system. Since the market is big and competition tough, effective patent protection provides invaluable tools for safeguarding the market position.

Moreover, the knowledge of key trends in the Russian legal landscape in terms of pharma patent litigation, intellectual property and regulatory issues, and approaches in interpreting the correlation between the IP aspects of competition regulations, may help to better understand the market situation from the legal prospective.

Litigation

Effective on June 1, 2016, important procedural amendments (obligatory complaint procedures) will come into force in terms of strategy that will affect pharma patent litigation. Currently patentees are not obliged to send cease-and-desist letters to potential defendants (manufacturers, distributors, importers of patent-infringing generic drugs).

Despite that, filing cease-and-desist letters without prior notice may have its advantages (eg, a surprise effect or a reason for the defendant to estimate the risks and stop infringing activities). Such letters may be recommended to ensure the framework for stating the bad-faith intention of the potential defendants or to seek an out-of-court settlement.

Starting from June 1, future pharma litigation lawsuits will be accompanied by evidence of the prior cease-and-desist letters sent to the defendants. A 30-day term shall pass from the date of sending the cease-and-desist letter to the defendants; otherwise the filed lawsuit will be returned to the plaintiff (which does not exclude re-filing the infringement case when the obligatory complaint procedure is complied with).

On January 1, 2016, new data exclusivity protection rules came into force in Russia. In particular, while it is still not allowed to use for commercial purposes the information on results of the pre-clinical and clinical trials—which is submitted by the originator for obtaining the marketing authorisation (MA) without the originator's consent for six years from the state registration of the original medicine in Russia—the provisions on filing the generic medicine application have changed.

That said, in comparison with the previous six years during which state registration of the generic medicine with use of the originator's data on pre-clinical and clinical trials was not allowed, after January 2016 the following changed:

An MA application for a generic medicine may be filed with the Russian Ministry of Health four years from the date of the state registration of an original medicine in Russia; and

An MA application for a biosimilar medicine may be filed with the Russian Ministry of Health three years from the date of the state registration of the original medicine in Russia.

In this regard, companies undertaking monitoring and compliance activities in Russia should adjust their internal policies (notification letters to the Russian Ministry of Health) to the extent reflecting the new legislative changes.

Russian law provides a five-year maximum for extending a pharma patent based on one MA. However, the wording of the legislation was unclear to the extent to which two or more patents may be extended based on one MA.

While considering the recent extension of nullity cases the Russian Intellectual Property Court correctly and in full compliance with the law established that the legislation does not prohibit extension of more than one patent based on one MA. The position of the IP Court in this regard may be used as an effective argument in patent extension nullity cases.

IP contests

Traditionally, IP-related agreements are exempt from the competition regulations, since IP is itself a legitimate monopoly.

Meanwhile, under Russian law parties may enter into agreements that at the same time may encompass the licensing provisions, sale and purchase aspects, as well the provisions potentially falling within competition control issues.

Russian competition legislation has detailed provisions on banning abuse of the market dominant positions; one of the forms of such abuse is a refusal by the dominant company to enter into a contract (eg, a supply agreement) when such a refusal is not economically or technologically explained.

However, the law provides that the requirements on banning abuse of market dominance do not apply to "activities on exercising the exclusive rights to IP results or means of individualisation". That provision may be characterised as an "IP defence" in cases of the dominant position abuse.

Recently, Russian judicial practice has faced issues relating to the implementation of the "IP defence" in cases where a medicine manufacturer refused to enter into a supply agreement with a distributor.

In 2010 the manufacturer and the distributor entered into a framework agreement under which the manufacturer, through separate agreements, would supply the patented and branded medicine (in its original package), while the distributor would re-package the medicine in the secondary package and start commercialising the medicine in Russia.

Later, the distributor sent a draft supply agreement to the manufacturer, who refused to enter into it. As it follows from the subsequent case file, the refusal was motivated by compliance reasons. The distributor filed a complaint with the Federal Antimonopoly Service (FAS) citing abuse of the dominant position. Upon investigation FAS established that the company holding the dominant position refused to enter into a supply agreement. The manufacturer appealed against the FAS decision to the Moscow City Commercial Court.

The court revoked the FAS decision, establishing that the refusal by the manufacturer to enter into a medicine supply agreement rested within the realm of the trademark owner's rights. Further, the court noted that the distributor had outstanding debts to the manufacturer.

FAS and the distributor appealed against the court decision to the Ninth Commercial Appellate Court, citing that FAS did not analyse the manufacturer's activities of using the exclusive rights, but the activities aimed at avoiding conclusion of the supply agreement. Furthermore, the appealing parties disagreed that the distributor had debts while the issue of debts incurred by the other companies in the distributor's group of entities was not relevant for the case.

In its opposition, the manufacturer cited that when an agreement had been entered into, trademarks rights would have been triggered. Further, the manufacturer submitted that the medicine at issue was protected with patents owned by the manufacturer.

The appellate court revoked the first instance decision and upheld the FAS decision. The reasoning of the appellate court was that as competition law states that refusal to enter into an agreement shall be motivated technologically, economically or otherwise, which would exclude the chance to enter into the supply agreement as had been defined in the framework agreement between the distributor and manufacturer.

In its decision, the appellate court agreed with FAS that the manufacturer's motives (the distributor's necessity to undergo compliance under the US Federal Corruption Practices Act; the intention of the manufacturer to commercialise the medicine via its subsidiary; and the debts incurred by the companies affiliated with the distributor) could not be recognised in this specific case as falling within "economical and technological motives".

While analysing the "IP defence" implementation in that particular case, the appellate court noted that the essence of the right to commercialise the medicine is the exclusive right of the patentee to make a decision on commercialisation of the medicine in Russia.

However, as the appellate court noted, the patentee shall take account of the competition law restrictions, which the court found to have been breached in the present case.

Meanwhile, the court also cited the "exhaustion of rights" defence—according to which commercialisation of a specific number of patent-protected products is not an infringement of exclusive rights if the same number of products has been previously supplied to Russia by the patentee or with its consent.

Further, regarding the invocation of "trademark rights", the court noted that the subject matter of the specific agreement in this case was in fact "supply of goods".

The appellate court decision was upheld by the Commercial Court of the Moscow region and the Russian Federation Supreme Court.

The implications of the case generally fall into line with the trends of the Russian competition regulator paying more attention to correlation between IP rights and the competition restrictions, which will require solid legal expertise for distribution chains.

The Russian IP legal landscape in which life sciences companies operate requires constant monitoring of legislative developments and trends in judicial practice to achieve knowledge-based tools in the current market situation.

Originally published by Life Sciences Intellectual Property Review.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

Authors
 
Some comments from our readers…
“The articles are extremely timely and highly applicable”
“I often find critical information not available elsewhere”
“As in-house counsel, Mondaq’s service is of great value”

Related Topics
 
Related Articles
 
Up-coming Events Search
Tools
Print
Font Size:
Translation
Channels
Mondaq on Twitter
 
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
 
Email Address
Company Name
Password
Confirm Password
Position
Mondaq Topics -- Select your Interests
 Accounting
 Anti-trust
 Commercial
 Compliance
 Consumer
 Criminal
 Employment
 Energy
 Environment
 Family
 Finance
 Government
 Healthcare
 Immigration
 Insolvency
 Insurance
 International
 IP
 Law Performance
 Law Practice
 Litigation
 Media & IT
 Privacy
 Real Estate
 Strategy
 Tax
 Technology
 Transport
 Wealth Mgt
Regions
Africa
Asia
Asia Pacific
Australasia
Canada
Caribbean
Europe
European Union
Latin America
Middle East
U.K.
United States
Worldwide Updates
Registration (you must scroll down to set your data preferences)

Mondaq Ltd requires you to register and provide information that personally identifies you, including your content preferences, for three primary purposes (full details of Mondaq’s use of your personal data can be found in our Privacy and Cookies Notice):

  • To allow you to personalize the Mondaq websites you are visiting to show content ("Content") relevant to your interests.
  • To enable features such as password reminder, news alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our content providers ("Contributors") who contribute Content for free for your use.

Mondaq hopes that our registered users will support us in maintaining our free to view business model by consenting to our use of your personal data as described below.

Mondaq has a "free to view" business model. Our services are paid for by Contributors in exchange for Mondaq providing them with access to information about who accesses their content. Once personal data is transferred to our Contributors they become a data controller of this personal data. They use it to measure the response that their articles are receiving, as a form of market research. They may also use it to provide Mondaq users with information about their products and services.

Details of each Contributor to which your personal data will be transferred is clearly stated within the Content that you access. For full details of how this Contributor will use your personal data, you should review the Contributor’s own Privacy Notice.

Please indicate your preference below:

Yes, I am happy to support Mondaq in maintaining its free to view business model by agreeing to allow Mondaq to share my personal data with Contributors whose Content I access
No, I do not want Mondaq to share my personal data with Contributors

Also please let us know whether you are happy to receive communications promoting products and services offered by Mondaq:

Yes, I am happy to received promotional communications from Mondaq
No, please do not send me promotional communications from Mondaq
Terms & Conditions

Mondaq.com (the Website) is owned and managed by Mondaq Ltd (Mondaq). Mondaq grants you a non-exclusive, revocable licence to access the Website and associated services, such as the Mondaq News Alerts (Services), subject to and in consideration of your compliance with the following terms and conditions of use (Terms). Your use of the Website and/or Services constitutes your agreement to the Terms. Mondaq may terminate your use of the Website and Services if you are in breach of these Terms or if Mondaq decides to terminate the licence granted hereunder for any reason whatsoever.

Use of www.mondaq.com

To Use Mondaq.com you must be: eighteen (18) years old or over; legally capable of entering into binding contracts; and not in any way prohibited by the applicable law to enter into these Terms in the jurisdiction which you are currently located.

You may use the Website as an unregistered user, however, you are required to register as a user if you wish to read the full text of the Content or to receive the Services.

You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these Terms or with the prior written consent of Mondaq. You may not use electronic or other means to extract details or information from the Content. Nor shall you extract information about users or Contributors in order to offer them any services or products.

In your use of the Website and/or Services you shall: comply with all applicable laws, regulations, directives and legislations which apply to your Use of the Website and/or Services in whatever country you are physically located including without limitation any and all consumer law, export control laws and regulations; provide to us true, correct and accurate information and promptly inform us in the event that any information that you have provided to us changes or becomes inaccurate; notify Mondaq immediately of any circumstances where you have reason to believe that any Intellectual Property Rights or any other rights of any third party may have been infringed; co-operate with reasonable security or other checks or requests for information made by Mondaq from time to time; and at all times be fully liable for the breach of any of these Terms by a third party using your login details to access the Website and/or Services

however, you shall not: do anything likely to impair, interfere with or damage or cause harm or distress to any persons, or the network; do anything that will infringe any Intellectual Property Rights or other rights of Mondaq or any third party; or use the Website, Services and/or Content otherwise than in accordance with these Terms; use any trade marks or service marks of Mondaq or the Contributors, or do anything which may be seen to take unfair advantage of the reputation and goodwill of Mondaq or the Contributors, or the Website, Services and/or Content.

Mondaq reserves the right, in its sole discretion, to take any action that it deems necessary and appropriate in the event it considers that there is a breach or threatened breach of the Terms.

Mondaq’s Rights and Obligations

Unless otherwise expressly set out to the contrary, nothing in these Terms shall serve to transfer from Mondaq to you, any Intellectual Property Rights owned by and/or licensed to Mondaq and all rights, title and interest in and to such Intellectual Property Rights will remain exclusively with Mondaq and/or its licensors.

Mondaq shall use its reasonable endeavours to make the Website and Services available to you at all times, but we cannot guarantee an uninterrupted and fault free service.

Mondaq reserves the right to make changes to the services and/or the Website or part thereof, from time to time, and we may add, remove, modify and/or vary any elements of features and functionalities of the Website or the services.

Mondaq also reserves the right from time to time to monitor your Use of the Website and/or services.

Disclaimer

The Content is general information only. It is not intended to constitute legal advice or seek to be the complete and comprehensive statement of the law, nor is it intended to address your specific requirements or provide advice on which reliance should be placed. Mondaq and/or its Contributors and other suppliers make no representations about the suitability of the information contained in the Content for any purpose. All Content provided "as is" without warranty of any kind. Mondaq and/or its Contributors and other suppliers hereby exclude and disclaim all representations, warranties or guarantees with regard to the Content, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. To the maximum extent permitted by law, Mondaq expressly excludes all representations, warranties, obligations, and liabilities arising out of or in connection with all Content. In no event shall Mondaq and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use of the Content or performance of Mondaq’s Services.

General

Mondaq may alter or amend these Terms by amending them on the Website. By continuing to Use the Services and/or the Website after such amendment, you will be deemed to have accepted any amendment to these Terms.

These Terms shall be governed by and construed in accordance with the laws of England and Wales and you irrevocably submit to the exclusive jurisdiction of the courts of England and Wales to settle any dispute which may arise out of or in connection with these Terms. If you live outside the United Kingdom, English law shall apply only to the extent that English law shall not deprive you of any legal protection accorded in accordance with the law of the place where you are habitually resident ("Local Law"). In the event English law deprives you of any legal protection which is accorded to you under Local Law, then these terms shall be governed by Local Law and any dispute or claim arising out of or in connection with these Terms shall be subject to the non-exclusive jurisdiction of the courts where you are habitually resident.

You may print and keep a copy of these Terms, which form the entire agreement between you and Mondaq and supersede any other communications or advertising in respect of the Service and/or the Website.

No delay in exercising or non-exercise by you and/or Mondaq of any of its rights under or in connection with these Terms shall operate as a waiver or release of each of your or Mondaq’s right. Rather, any such waiver or release must be specifically granted in writing signed by the party granting it.

If any part of these Terms is held unenforceable, that part shall be enforced to the maximum extent permissible so as to give effect to the intent of the parties, and the Terms shall continue in full force and effect.

Mondaq shall not incur any liability to you on account of any loss or damage resulting from any delay or failure to perform all or any part of these Terms if such delay or failure is caused, in whole or in part, by events, occurrences, or causes beyond the control of Mondaq. Such events, occurrences or causes will include, without limitation, acts of God, strikes, lockouts, server and network failure, riots, acts of war, earthquakes, fire and explosions.

By clicking Register you state you have read and agree to our Terms and Conditions